|
Feb 07, 2023
|
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
SOUTH PLAINFIELD, N.J. , Feb. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2022 financial results and provide an update on the company's business and outlook on Tuesday,
|
|
|
Feb 03, 2023
|
PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
- This award recognizes PTC's 25-year legacy in discovering and delivering novel therapies that address the underlying cause of rare diseases - SOUTH PLAINFIELD, N.J. , Feb. 3, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of
|
|
|
Feb 02, 2023
|
PTC Therapeutics to Participate at Upcoming Investor Conference
SOUTH PLAINFIELD, N.J. , Feb. 2, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: SVB Securities Global Biopharma Conference Tuesday, Feb. 14 at 9:20 a.m.
|
|
|
Jan 19, 2023
|
NICE Recommends Reimbursement for Translarna™
- Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J. , Jan. 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final
|
|
|
Jan 17, 2023
|
PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community
- 2023 Program to Focus on Innovation and Transition to Adulthood Initiatives – - Submissions Due March 17, 2023 - SOUTH PLAINFIELD, N.J. , Jan. 17, 2023 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced the launch of the ninth annual STRIVE™ awards program.
|
|
|
Jan 11, 2023
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Jan. 11, 2023 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023 , the company approved non-statutory stock options to purchase an aggregate of 39,585 shares of its common stock and 13,045 restricted stock units ("RSUs"), each
|
|
|
Jan 09, 2023
|
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference
- ~$710 million unaudited 2022 total revenue, representing an impressive over 30% year-over-year growth – - $940 million - $1.0 billion 2023 total revenue guidance – - Results from three registration-directed clinical trials expected in 2023 – - One additional registration-directed clinical
|
|
|
Jan 04, 2023
|
PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference
SOUTH PLAINFIELD, N.J. , Jan. 4, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, Jan. 9 , at 7:30 a.m. PST / 10:30 a.m. EST .
|
|
|
Dec 01, 2022
|
Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy
- First global regulatory approval for treatment of this rare genetic disease - SOUTH PLAINFIELD, N.J. , Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency , ANVISA (Agência Nacional de Vigilância Sanitária), has approved
|
|
|
Nov 17, 2022
|
Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
- Upstaza ™ is the first gene therapy infused directly into the brain for the treatment of AADC deficiency - - MHRA authorization follows recent European Union authorization - - AADC deficiency is a rare, fatal disorder that arrests motor development causing severe disability - SOUTH PLAINFIELD,
|
|
